Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance.

ABSTRACT:

Objective

The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced virologically suppressed people living with HIV (PLWH). We analyzed virologic outcomes with respect to treatment history and HIV drug resistance.

Design

Post hoc analysis of a randomized trial.

Methods

Main inclusion criteria were an HIV RNA level < 50 copies/mL for ≥ 24 weeks and no resistance to integrase strand transfer inhibitors or bDRV. Resistance-associated mutations (RAMs) were interpreted using the Stanford HIVdb mutation list. Outcomes measures were 48-week virologic response (HIV RNA < 50 copies/mL, FDA snapshot) and HI

SUBMITTER: Wolf E 

PROVIDER: S-EPMC8425038 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature